Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CNTA 
Centessa Pharmaceuticals PLC ADR (CNTA)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: CNTA (5-star) is a REGULAR-BUY. BUY since 20 days. Simulated Profits (-3.98%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $37.67
1 Year Target Price $37.67
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 120.98% | Avg. Invested days 42 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.87B USD | Price to earnings Ratio - | 1Y Target Price 37.67 |
Price to earnings Ratio - | 1Y Target Price 37.67 | ||
Volume (30-day avg) 11 | Beta 1.56 | 52 Weeks Range 9.60 - 30.58 | Updated Date 12/14/2025 |
52 Weeks Range 9.60 - 30.58 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1425.33% |
Management Effectiveness
Return on Assets (TTM) -25.26% | Return on Equity (TTM) -60.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3790751317 | Price to Sales(TTM) 258.16 |
Enterprise Value 3790751317 | Price to Sales(TTM) 258.16 | ||
Enterprise Value to Revenue 252.72 | Enterprise Value to EBITDA 1.12 | Shares Outstanding 146075743 | Shares Floating 80094609 |
Shares Outstanding 146075743 | Shares Floating 80094609 | ||
Percent Insiders 0.43 | Percent Institutions 87.44 |
About Centessa Pharmaceuticals PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-05-28 | CEO & Director Dr. Saurabh Saha M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 114 | Website https://centessa.com |
Full time employees 114 | Website https://centessa.com | ||
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.